Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid-19 entities : Veru inc. save search
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
Published: 2023-05-04 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.06%
H: 0.29%
C: -0.7%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.0%
H: 2.36%
C: 0.0%
covid-19 fda sabizabulin treatment risk trial agreement
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
Published: 2023-04-04 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.38%
H: 1.97%
C: 0.72%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 7.89%
H: 1.63%
C: -9.76%
covid-19 sabizabulin respiratory update preclinical program results
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-11-10 (Crawled : 02:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -58.83%
H: 25.89%
C: 12.78%
covid-19 fda risk sabizabulin meeting respiratory authorization update
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk
Published: 2022-09-19 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting review authorization
Veru Announces FDA has Updated the Meeting Date for the Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-19 (Crawled : 17:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.01%
C: -0.45%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -5.6%
H: 0.74%
C: -13.28%
covid-19 fda risk sabizabulin meeting respiratory review authorization
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
Published: 2022-09-14 (Crawled : 12:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 1.89%
H: 3.06%
C: 0.64%
covid-19 risk sabizabulin pharma services commercial respiratory agreement
Veru Announces Date for FDA Advisory Committee Meeting to Review Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-09-07 (Crawled : 18:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.64%
H: 1.18%
C: 0.92%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 9.6%
H: 3.38%
C: -28.02%
covid-19 fda risk sabizabulin meeting respiratory review authorization
Veru Granted Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration
Published: 2022-08-22 (Crawled : 13:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.15%
H: 1.08%
C: 0.25%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 5.44%
H: 3.53%
C: -7.93%
covid-19 treatment sabizabulin granted
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
Published: 2022-08-19 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.61%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.25%
H: 2.6%
C: 1.66%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -3.19%
H: 7.78%
C: -3.37%
covid-19 disease international
Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.82%
H: 26.51%
C: 12.59%
covid-19 treatment sabizabulin
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Published: 2022-08-09 (Crawled : 15:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.86%
H: 0.53%
C: -0.68%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.5%
H: 2.25%
C: -4.17%
covid-19 treatment risk sabizabulin respiratory presentation study
European Medicines Agency’s Emergency Task Force Has Initiated the Review of Veru's Sabizabulin Treatment for Hospitalized COVID-19 Patients for Emergency Use in European Union Countries
Published: 2022-07-27 (Crawled : 15:20) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.78%
H: 0.57%
C: -0.01%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.81%
H: 3.05%
C: 1.2%
covid-19 treatment sabizabulin review initiated
UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized COVID-19 Patients
Published: 2022-07-25 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 1.07%
C: 0.85%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 3.41%
H: 0.07%
C: -8.65%
covid-19 treatment sabizabulin application review authorization
Veru, Immunome Tout Positive Data for COVID-19 Therapeutics
Published: 2022-07-06 (Crawled : 17:00) - biospace.com/
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
IMNM | $15.5 -9.78% -10.84% 2.1M
|
Health Technology
|
| O: 2.63%
H: 12.54%
C: 9.69%
covid-19 therapeutics positive
Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
Published: 2022-07-06 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.85%
H: 1.45%
C: 0.66%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.26%
H: 20.43%
C: 12.73%
covid-19 treatment sabizabulin trial results publication phase 3
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS
Published: 2022-06-07 (Crawled : 11:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -2.57%
H: 17.21%
C: 13.21%
covid-19 fda risk drug antiviral application authorization emergency use authorization
Veru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 Patients
Published: 2022-05-18 (Crawled : 17:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 2.18%
H: 2.7%
C: -5.83%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.91%
H: 0.0%
C: 0.0%
covid-19 disease
Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
Published: 2022-05-12 (Crawled : 11:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.09%
H: 3.06%
C: 2.99%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -24.43%
H: 26.44%
C: 23.7%
covid-19 sabizabulin authorization emergency use authorization
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.